International Journal of General Medicine (Oct 2021)
The Association between Thyroid-Stimulating Hormone and Long-Term Outcomes in Patients with ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
Abstract
Yuansong Zhu, Jian Shen, Yuzhou Xue, Zhenxian Xiang, Yi Jiang, Wei Zhou, Suxin Luo Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence: Suxin LuoDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, People’s Republic of ChinaTel +86 23 8901 1562Fax +86 23 89011429Email [email protected]: Thyroid hormones are closely related to the cardiovascular system. Our study aimed to explore the impact of admission thyroid-stimulating hormone (TSH) levels on long-term outcomes in patients with acute ST segment elevation myocardial infarction (STEMI) by detailed stratifications of TSH.Methods: Consecutive STEMI patients admitted to our hospital were divided into four groups: Group 1 (TSH 3.5 mIU/L). The primary endpoint was all-cause mortality during follow-up, and the median follow-up was 2.5 years. Cox proportional hazard regression models were performed to identify the prognostic value of TSH.Results: A total of 1186 patients were included. Group 4 was presented with higher systolic and diastolic blood pressure (all P I, P = 0.014). During follow-up, 138 deaths occurred. Patients in Group 4 had the worst long-term outcomes (P 3.5 mIU/L was identified as an independent risk factor for long-term mortality after STEMI.Conclusion: Only TSH elevation beyond the normal range was associated with worse long-term prognosis in STEMI patients, while high-normal TSH or reduced TSH did not alter long-term prognosis of STEMI patients. TSH > 3.5 mIU/L was an independent risk factor for long-term mortality in STEMI.Keywords: acute myocardial infarction, thyroid hormone, thyroid-stimulating hormone, STEMI, TSH
